AbbVie (ABBV) Stock Forecast & Price Target

Compare

22,792 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABBV Analyst Ratings

Moderate Buy

9 Buy

6 Hold

0 Sell

Based on 15 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$209.33

▲(11.04%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $209.33 with a high forecast of $250.00 and a low forecast of $170.00. The average price target represents a 11.04% change from the last price of $188.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"161":"$161","206":"$206","251":"$251","183.5":"$183.5","228.5":"$228.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$250.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":209.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$209.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$170.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[161,183.5,206,228.5,251],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,188.36,193.10153846153847,197.84307692307692,202.5846153846154,207.32615384615386,212.0676923076923,216.80923076923077,221.55076923076922,226.2923076923077,231.03384615384616,235.7753846153846,240.5169230769231,245.25846153846152,{"y":250,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,188.36,189.97307692307695,191.58615384615385,193.19923076923078,194.8123076923077,196.42538461538464,198.03846153846155,199.65153846153848,201.2646153846154,202.8776923076923,204.49076923076925,206.10384615384618,207.71692307692308,{"y":209.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,188.36,186.9476923076923,185.53538461538463,184.12307692307692,182.71076923076924,181.29846153846154,179.88615384615386,178.47384615384615,177.06153846153848,175.64923076923077,174.2369230769231,172.82461538461538,171.4123076923077,{"y":170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":162.99,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.16,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.9,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$250.00

Average Price Target$209.33

Lowest Price Target$170.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$208

Hold

10.33%

Upside

Reiterated

07/24/25

AbbVie's overall score is driven by strong financial performance and positive earnings call results, particularly in its Ex-Humira platform. However, high leverage and an elevated P/E ratio pose risks. Technical indicators provide a neutral outlook, suggesting the stock is reasonably positioned but requires careful monitoring of debt levels and valuation.

Vamil DivanGuggenheim

Guggenheim

$216

Buy

14.58%

Upside

Reiterated

07/22/25

Guggenheim Reaffirms Their Buy Rating on AbbVie (ABBV)We are updating our AbbVie model; we reiterate our Buy rating and maintain our $216 price target.

Geoff MeachamCiti

Citi

$205

Hold

8.74%

Upside

Reiterated

07/21/25

AbbVie (ABBV) Receives a Hold from Citi

Gary NachmanRaymond James

Raymond James

$190.58→$227

Buy

20.41%

Upside

Reiterated

07/17/25

Raymond James Sticks to Their Buy Rating for AbbVie (ABBV)

Luisa HectorBerenberg Bank

Berenberg Bank

$170

Hold

-9.82%

Downside

Reiterated

07/14/25

AbbVie (ABBV) Gets a Hold from Berenberg Bank

Unknown AnalystEvercore ISI

Not Ranked

Evercore ISI

$205

Buy

8.74%

Upside

Reiterated

07/11/25

SMID Biotech Week in Review

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/10/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Alkermes (NASDAQ: ALKS)

Terence FlynnMorgan Stanley

Morgan Stanley

$250

Buy

32.61%

Upside

Reiterated

07/10/25

AbbVie (ABBV) Receives a Buy from Morgan Stanley

Chris SchottJ.P. Morgan

J.P. Morgan

$200

Buy

6.09%

Upside

Reiterated

07/10/25

AbbVie: A Strong Buy with Promising Growth Prospects and Stable Outlook

Evan SeigermanBMO Capital

BMO Capital

$215

Buy

14.05%

Upside

Reiterated

07/09/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mohit BansalWells Fargo

Wells Fargo

$240

Buy

27.31%

Upside

Reiterated

07/08/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Cigna (NYSE: CI) and Brookdale Senior Living (NYSE: BKD)

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Esperion (NASDAQ: ESPR)

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

06/30/25

AbbVie's Strategic Acquisition of Capstan Therapeutics: A High-Risk, High-Reward Move in Immunology

Asad HaiderGoldman Sachs

Goldman Sachs

$194→$197

Hold

4.50%

Upside

Reiterated

06/10/25

Balanced Outlook for AbbVie: Hold Rating Amid Opportunities and Challenges

Tim AndersonBank of America Securities

Bank of America Securities

$204

Hold

8.21%

Upside

Reiterated

06/06/25

Bank of America Securities Remains a Hold on AbbVie (ABBV)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$208

Hold

10.33%

Upside

Reiterated

07/24/25

Vamil DivanGuggenheim

Guggenheim

$216

Buy

14.58%

Upside

Reiterated

07/22/25

Guggenheim Reaffirms Their Buy Rating on AbbVie (ABBV)We are updating our AbbVie model; we reiterate our Buy rating and maintain our $216 price target.

Geoff MeachamCiti

Citi

$205

Hold

8.74%

Upside

Reiterated

07/21/25

AbbVie (ABBV) Receives a Hold from Citi

Gary NachmanRaymond James

Raymond James

$190.58→$227

Buy

20.41%

Upside

Reiterated

07/17/25

Raymond James Sticks to Their Buy Rating for AbbVie (ABBV)

Luisa HectorBerenberg Bank

Berenberg Bank

$170

Hold

-9.82%

Downside

Reiterated

07/14/25

AbbVie (ABBV) Gets a Hold from Berenberg Bank

Unknown AnalystEvercore ISI

Not Ranked

Evercore ISI

$205

Buy

8.74%

Upside

Reiterated

07/11/25

SMID Biotech Week in Review

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/10/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Alkermes (NASDAQ: ALKS)

Terence FlynnMorgan Stanley

Morgan Stanley

$250

Buy

32.61%

Upside

Reiterated

07/10/25

AbbVie (ABBV) Receives a Buy from Morgan Stanley

Chris SchottJ.P. Morgan

J.P. Morgan

$200

Buy

6.09%

Upside

Reiterated

07/10/25

AbbVie: A Strong Buy with Promising Growth Prospects and Stable Outlook

Evan SeigermanBMO Capital

BMO Capital

$215

Buy

14.05%

Upside

Reiterated

07/09/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mohit BansalWells Fargo

Wells Fargo

$240

Buy

27.31%

Upside

Reiterated

07/08/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Cigna (NYSE: CI) and Brookdale Senior Living (NYSE: BKD)

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Esperion (NASDAQ: ESPR)

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

06/30/25

AbbVie's Strategic Acquisition of Capstan Therapeutics: A High-Risk, High-Reward Move in Immunology

Asad HaiderGoldman Sachs

Goldman Sachs

$194→$197

Hold

4.50%

Upside

Reiterated

06/10/25

Balanced Outlook for AbbVie: Hold Rating Amid Opportunities and Challenges

Tim AndersonBank of America Securities

Bank of America Securities

$204

Hold

8.21%

Upside

Reiterated

06/06/25

Bank of America Securities Remains a Hold on AbbVie (ABBV)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

14/22 ratings generated profit

Average Return

+1.84%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +1.84% per trade.

3 Months

xxx

Success Rate

16/22 ratings generated profit

Average Return

+6.42%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +6.42% per trade.

1 Year

Mohit BansalWells Fargo

Success Rate

21/22 ratings generated profit

Average Return

+14.53%

reiterated a buy rating 22 days ago

Copying Mohit Bansal's trades and holding each position for 1 Year would result in 95.45% of your transactions generating a profit, with an average return of +14.53% per trade.

2 Years

xxx

Success Rate

40/41 ratings generated profit

Average Return

+39.38%

assigned a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 97.56% of your transactions generating a profit, with an average return of +39.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABBV has received 19 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 209.33.

Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $2.88 with a range of $2.82 to $3.00. The previous quarter’s EPS was $2.46. ABBV beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.95% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $15.03B with a range of $14.80B to $15.21B. The previous quarter’s sales results were $13.34B. ABBV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.37% of the time in the same period. In the last calendar year ABBV has Outperformed its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 209.33.

What is ABBV’s upside potential, based on the analysts’ average price target?

AbbVie has 11.04% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABBV a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy which is based on 9 buy ratings, 6 hold ratings and 0 sell ratings.

What is AbbVie’s price target?

The average price target for AbbVie is 209.33. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $250.00 ,the lowest forecast is $170.00. The average price target represents 11.04% Increase from the current price of $188.52.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of ABBV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AbbVie (ABBV) Stock Forecast & Price Target

ABBV Analyst Ratings

ABBV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

ABBV Analyst Recommendation Trends

ABBV Financial Forecast

ABBV Earnings Forecast

ABBV Sales Forecast

ABBV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts